Alumis Stock Rises on Strong Psoriasis Data, Partnership Signals, and Insider Buying

Shares of Alumis (ALMS) rallied 6.3% in pre-market trading Wednesday following a series of positive developments, including strong clinical data for its lead drug candidate and a significant insider stock purchase.

Data Reinforces Drug Potential

At the Cantor Fitzgerald Global Healthcare Conference on September 9, Alumis management presented encouraging long-term data for its psoriasis treatment, envudeucitinib. The presentation highlighted the drug's durability and effectiveness in ongoing studies.

Key data points for patients with moderate-to-severe plaque psoriasis included:

• Approximately 40% achieved complete skin clearance at six months.
• This figure increased to around 55% at 48 weeks.

Management also reiterated its strategy for the drug following mixed results in a recent lupus trial, stating a focused path forward targeting a specific biomarker-defined patient subgroup. The company remains on track to submit a New Drug Application (NDA) to the FDA for envudeucitinib in psoriasis in the fourth quarter of 2026.

Ad

Partnership Talks and Insider Confidence

Adding to investor optimism, company leadership signaled it is actively evaluating partnership arrangements to expand the drug's global reach. Management commentary at both the Cantor event and the Wells Fargo Healthcare Conference on September 8 emphasized that an ideal partner would help develop envudeucitinib across a broad range of indications.

This strategic outlook was bolstered by a significant show of insider conviction. According to filings, director Srinivas Akkaraju purchased more than 986,000 shares in open-market transactions on September 4 and September 8. The combined value of these purchases exceeded $10.7 million. While Akkaraju also sold a smaller block of roughly 96,000 shares in the same period, the net investment is a substantial signal of confidence from a board member.

Market Context

The stock's upward movement was driven almost entirely by company-specific news, occurring against a largely neutral market backdrop. The rally helps Alumis recover ground lost after the stock came under pressure following a disappointing trial update for lupus on September 1. The combination of strong clinical data, a clear commercialization strategy, and substantial insider buying created a constructive catalyst for the shares.